Compare

KLOW Blend vs Tesamorelin

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

KLOW Blend

2233 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 67% · Mixed 24% · Unfavorable overall 9%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Energy
-124
Mood
-50
Focus
-86
Sleep quality
-136
Lean mass
-164

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Dizziness
-28
Fatigue
-151
Nausea
-121
Water retention
-140
Appetite loss
-165

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg

Reports span 0.01–3 mg

0.01–0.025 mg
2
0.025–0.05 mg
10
0.05–0.1 mg
18
0.1–0.2 mg
21
0.2–0.4 mg
26
0.4–0.6 mg
18
0.6–1 mg
10
1–2 mg
7
2–3 mg
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing37stacking25side effects33klow blend16

How repeat users are trending

Among repeat reporters, 62% said they felt similar to their last entry, 41% more positive, and 17% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 15 days · Based on 491 repeat reporters

Tesamorelin

621 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 45% · Mixed 38% · Unfavorable overall 17%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Skin appearance
168
Appetite control
76
Energy
65
Mood
41
Focus
150

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Headache
84
GI discomfort
156
Dizziness
30
Fatigue
36
Nausea
150

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg

Reports span 0.01–2 mg

0.01–0.025 mg
4
0.025–0.05 mg
11
0.05–0.1 mg
18
0.1–0.2 mg
25
0.2–0.4 mg
28
0.4–0.6 mg
23
0.6–1 mg
17
1–2 mg
11

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing25stacking28side effects11tesamorelin29

How repeat users are trending

Among repeat reporters, 55% said they felt similar to their last entry, 43% more positive, and 15% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 32 days · Based on 137 repeat reporters

Sources (10)

Published sources linked on the KLOW Blend and Tesamorelin wiki pages.

  1. PubMed

    Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract

    Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018

    Source
    Wiki study page →
  2. PubMed

    Thymosin beta 4 and wound healing: a multifunctional peptide

    Goldstein AL, Kleinman HK. Expert Opin Biol Ther. 2010

    Source
    Wiki study page →
  3. Review Article

    GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes

    Pickart L, Margolina A. Cosmetics. 2018

    Source
    Wiki study page →
  4. FDA Drug Label

    EGRIFTA (tesamorelin) for injection - Prescribing Information

    Theratechnologies. FDA Drug Label. 2010

    Source
    Wiki study page →
  5. PubMed

    Growth hormone-releasing peptides: clinical applications

    Ghigo E, Arvat E, Camanni F. Endocrine. 2008

    Source
    Wiki study page →
  6. ClinicalTrials.gov

    Tesamorelin HIV lipodystrophy studies on ClinicalTrials.gov

    ClinicalTrials.gov. Clinical trial registry. 2024

    Source
    Wiki study page →
  7. FDA Drug Label

    EGRIFTA SV (tesamorelin) for injection - Prescribing Information

    Theratechnologies. FDA Drug Label. 2019

    Source
    Wiki study page →
  8. PubMed

    Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy

    Spooner LM, Olin JL. The Annals of pharmacotherapy. 2012

    Source
    Wiki study page →